Ontology highlight
ABSTRACT:
SUBMITTER: Nientiedt C
PROVIDER: S-EPMC5496866 | biostudies-other | 2017 Jul
REPOSITORIES: biostudies-other
Nientiedt Cathleen C Heller Martina M Endris Volker V Volckmar Anna-Lena AL Zschäbitz Stefanie S Tapia-Laliena María A MA Duensing Anette A Jäger Dirk D Schirmacher Peter P Sültmann Holger H Stenzinger Albrecht A Hohenfellner Markus M Grüllich Carsten C Duensing Stefan S
Scientific reports 20170704 1
Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1 ...[more]